Prognostic outcomes in Japanese patients with metastatic castration‐sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor

Abstract

ObjectiveThe objective of this study was to compare the prognostic outcomes between metastatic castration‐sensitive prostate cancer (mCSPC) patients receiving conventional androgen deprivation therapy (ADT) and those receiving ADT plus a novel androgen‐receptor signaling inhibitor (ARSI) in routine clinical practice in Japan.MethodsThis was conducted as a retrospective multicenter study including 581 mCSPC patients, consisting of 305 receiving ADT alone or in combination with bicalutamide (group 1) and 276 receiving ADT plus one of the following ARSIs: abiraterone acetate, apalutamide, or enzalutamide (group 2). Prognostic outcomes between these 2 groups were comprehensively compared.ResultsIn the entire cohort, prostate‐specific antigen—progression‐free survival (PSA‐PFS) in group 2 was significantly longer than that in group 1, while no significant difference was noted in overall survival (OS) between the two groups. In patients corresponding to the LATITUDE high‐risk group, however, both PSA‐PFS and OS in group 2 were significantly longer than those in group 1. Of several factors examined, the following were identified as independent predictors of poor PSA‐PFS in the entire cohort as well as the LATITUDE high‐risk group: high C‐reactive protein, high lactate dehydrogenase, high alkaline phosphatase, high Gleason score, and group 1. Furthermore, it was possible to precisely classify both the entire cohort and LATITUDE high‐risk group into 3 risk groups regarding PSA‐PFS according to the positive numbers of independent factors: positive for ≤1 factor, favorable; 2 factors, intermediate; and ≥3 factors, poor.ConclusionCombined use of ARSIs with ADT could improve the prognostic outcomes of mCSPC patients, particularly those in the LATITUDE high‐risk group, in real‐world clinical practice in Japan.